1. Home
  2. CSR vs DRUG Comparison

CSR vs DRUG Comparison

Compare CSR & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo D/B/A Centerspace

CSR

D/B/A Centerspace

HOLD

Current Price

$55.41

Market Cap

931.7M

Sector

Real Estate

ML Signal

HOLD

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

SELL

Current Price

$49.81

Market Cap

778.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CSR
DRUG
Founded
1970
2019
Country
United States
United States
Employees
349
N/A
Industry
Real Estate Investment Trusts
Pharmaceuticals and Biotechnology
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
931.7M
778.4M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CSR
DRUG
Price
$55.41
$49.81
Analyst Decision
Hold
Strong Buy
Analyst Count
9
8
Target Price
$64.14
★ $151.95
AVG Volume (30 Days)
★ 389.6K
75.2K
Earning Date
11-02-2026
08-17-2026
Dividend Yield
★ 5.58%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$62.27
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$52.00
$48.53
52 Week High
$69.61
$123.75

Technical Indicators

Market Signals
Indicator
CSR
DRUG
Relative Strength Index (RSI) 50.97 25.33
Support Level $54.07 N/A
Resistance Level $57.76 $78.35
Average True Range (ATR) 0.99 2.99
MACD -0.17 -0.60
Stochastic Oscillator 35.42 11.85

Price Performance

Historical Comparison
CSR
DRUG

About CSR D/B/A Centerspace

Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: